Correlation Engine 2.0
Clear Search sequence regions

  • antibodies (3)
  • deuterium (1)
  • G protein (4)
  • gq g- proteins (1)
  • GTP (2)
  • half life (1)
  • humans (1)
  • hydrogen (1)
  • ligand (1)
  • mass (1)
  • osteoporosis (1)
  • phage (1)
  • protein human (1)
  • PTH1R (8)
  • receptor (3)
  • receptor 1 (3)
  • serum (1)
  • signal (2)
  • β arrestin (4)
  • Sizes of these terms reflect their relevance to your search.

    Parathyroid hormone receptor 1 (PTH1R) is a class B G-protein coupled receptor with key roles in bone development. The receptor signals through both the Gs and Gq G-proteins as well as through β-arrestin in a G-protein independent manner. Current treatments for bone disorders, such as osteoporosis, target the PTH1R but are suboptimal in their efficacy. Monoclonal antibodies represent a major growth area in therapeutics as a result of their superior specificity and long serum half-life. Here, we discovered antibodies against the extracellular domain (ECD) of PTH1R from a phage display library. One of these antibodies, ECD-ScFvhFc, binds PTH1R with high affinity and although it has little or no effect on G-protein dependent receptor signaling, it does reduce PTH1R mediated β-arrestin signaling. Hydrogen-deuterium exchange mass spectrometry (HDX-MS) demonstrated that the ECD-ScFvhFc binding site overlapped partially with that of the cognate ligand, PTH. The results of this study demonstrate the suitability of PTH1R as a target for therapeutic antibody development. Copyright © 2022 Elsevier Inc. All rights reserved.


    Kaushik Sarkar, Lisa Joedicke, Marta Westwood, Rebecca Burnley, Michael Wright, David McMillan, Bernadette Byrne. Modulation of PTH1R signaling by an extracellular binding antibody. Vitamins and hormones. 2022;120:109-132

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 35953107

    View Full Text